Cell-therapy due diligence for patients in Canada
A country-specific starting point for checking product authorisation, trial oversight and cross-border follow-up. This page does not rank providers or recommend medical travel.
What the regulator can confirm
Health Canada warns about unauthorised cell therapies and unproven health claims. Its Drug Product Database covers products authorised for sale, while the Canadian Clinical Trial Search Portal covers trials that met Canadian regulatory requirements. Trial authorisation is not marketing authorisation or proof of efficacy.
For treatment in Canada, verify the product in the appropriate Health Canada record. For treatment abroad, identify the foreign legal route and manufacturer and plan how adverse events will be managed and reported after return. Do not assume that autologous cells are exempt merely because they came from the same patient.
Evidence to request before treatment
| Question | Document or identifier | Why it matters |
|---|---|---|
| What exactly is administered? | Product name, cell source, processing, dose and route | Evidence and legal status are product- and indication-specific. |
| What is the legal route? | Marketing authorisation, authorised trial number, or named exemption and authority | A clinic licence or registry listing does not by itself authorise a product. |
| Who manufactures it? | Legal manufacturer, site and authorisation scope | General references to GMP are not a substitute for a current, applicable record. |
| How are harms managed? | Consent form, adverse-event plan, insurance and emergency contact | Experimental status does not remove the duty to disclose and manage risk. |
| What happens after travel? | Written follow-up plan and named clinician | Cross-border care can complicate continuity and reporting. |
Conditions compared
Educational regulatory orientation, reviewed in 2026. Verify current records directly with the authority and seek independent medical advice.